Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,017.00-36.9
Stock Analysis, IPO, Mutual Funds, Bonds & More
Dr Reddy's launches generic oral anti-epileptic drug in US

The product is a generic version of Lundbeck's Sabril powder for oral solution, Dr Reddy's said in a filing to the BSE.

Dr Reddy's launches Roche's Avastin biosimilar in India

The launch of Versavo is another step in that journey and helps in strengthening the company's oncology portfolio.

USFDA okays new antibiotic for highly drug-resistant tuberculosis

Pretomanid, a new chemical entity, was under development since 2002 by the TB Alliance.

Pharma wants a booster fund to push innovation

Indian Pharmaceutical Alliance seeks to promote innovation backed by risk capital.

Sun, CSIR-IICT Ink Global Licensing Pact for Patents

'This collaboration with CSIRIICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline.'

Unichem Laboratories gets USFDA nod for hypertension management drug

The approved product is a generic version of Hygroton tablets, 25 mg and 50 mg of Sanofi Aventis US, LLC.

USFDA issues 6 observations to Natco Pharma's API facility near Hyderabad

The United States Food and Drug Administration (USFDA) conducted inspection at Kothur facility between August 5-9, 2019.

At Rs 58.8 cr, Murali of Divi's Lab highest paid Indian pharma executive

The percentage increase in the median remuneration for the staff of the firm for FY19 was 3.96 per cent.

Facing headwinds in US, Natco Pharma looks to scale up business in China

In the near term, the pharmaceutical company would continue to be driven by markets like India, Brazil and Canada.

Not withholding interim compensation from patients who want more: Johnson and Johnson to HC

The submission by the company came in response to a query by Justice Vibhu Bakhru as to what was it doing in cases where patients want more than the Rs 25 lakh.

US senator seeks unannounced inspections of foreign drug manufacturing units in India and China

US senator seeks unannounced inspections of foreign drug manufacturing units in India and China

The chairman of the Senate Finance Committee said this was needed as these facilities provided most of the ingredients for production inside the US.

NCLAT stays eviction of Sterling Biotech from its premise

NCLAT stays eviction of Sterling Biotech from its premise

Besides, the appellate tribunal also said that "the Liquidator cannot sell the assets of the premises in question."

Sun Pharma shuts 2 Gujarat R&D centres to cut costs

Sun Pharma shuts 2 Gujarat R&D centres to cut costs

Sources said the company’s R&D centre at Gurgaon (started by erstwhile Ranbaxy) will now undertake the clinical research handled by the Vadodara facility

Mylan deal to give a boost to Pfizer’s India business: Analysts

Mylan deal to give a boost to Pfizer’s India business: Analysts

On Monday, Pfizer and Mylan announced that as per the Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company.

Warning letter woes: Dr Reddy's expects FDA inspection of AP plant by year-end

Warning letter woes: Dr Reddy's expects FDA inspection of AP plant by year-end

USFDA had issued warning letter in November 2015 relating to Current Good Manufacturing Practice deviations at DR Reddy's API manufacturing facilities at Srikakulam.

Strides inks JV pact with China's Sihuan Pharma

Strides inks JV pact with China's Sihuan Pharma

Sihuan will leverage its over 4,000 strong sales force and 3,000 plus distributors across Mainland China to market the products.

PHARMACEUTICALS STOCKS
NSE
BSE

Company NameLatestChange%ChangeVolume
Nifty Pharma7749.78.350.110
Sun Pharmaceutical Industries420.9-5.1-1.25151625
Earnest Healthcare Ltd.0000
Dr Reddys Laboratories2554.645.51.81609510
Divis Laboratories1522.154.050.27382353
Yogi Healthcare Ltd.0000
Load More...
1

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service

BACK TO TOP